 |
Imbruvica |
Ratified the Food and Drug Administration "FDA" America, in the thirteenth of the month of November, the issuance of preparation pharmacist new treatment for a blood cancers serious and rare , which is known as cancer cells Mantell nodes "mantle cell lymphoma", a cause to attack tumor cells of the contract lymph and bone marrow .
The property known as "Imbruvica", and contains the active substance "ibrutinib", and there in the form of capsules, available in a small package containing 60 capsules , with a concentration per 140 mg capsule .
The innovative medicine , is the third drug for the treatment of people living with cancer is rare , " mantle cell lymphoma " , and that after the ratification of the drug " Velcade " in the year 2006, and the drug "Revlimid" during this year.
And the mechanism of action of the new drug "Imbruvica", pointed Food and Drug Administration "FDA" that the inhibition of enzymes needed by cancer Ki spreads and doubles , and has undergone about 111 people for clinical trials of medicine , where he showed 66% of the number of cases contraction evident in the size of tumor cells and, as some of them completely disappeared with the end of therapeutic course .
